Neon Therapeutics Garners $70,000,000 Series B Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1676734f-3acc-487c-b243-0435ea2abc54 - Date
1/6/2017 - Company Name
Neon Therapeutics - Mailing Address
215 First Street Cambridge, MA 02142 USA - Company Description
We have assembled a team of world experts in cancer immunotherapy to develop therapies that target abnormal proteins called neoantigens, which are produced by cancer cells. - Website
http://www.neontherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$70,000,000 - Transaction Round
Series B - Proceeds Purposes
Proceeds from the financing will be used to advance Neon Therapeutics’ lead program NEO-PV-01, a fully personalized neoantigen vaccine, through an ongoing Phase 1b clinical trial. In addition, this investment will support preclinical development of NEO-PTC-01, a personalized adoptive T cell program, and the Shared Neoantigen Program. - M&A Terms
- Venture Investor
Partner Fund Management - Venture Investor
Third Rock Ventures - Venture Investor
Access Industries - Venture Investor
Fidelity Management & Research Company - Venture Investor
Wellington Management Company - Venture Investor
Nextech Invest
